白血病（leukemia） - 医教在线—高效率医学在线自学平台.pptVIP

* At the molecular level, imatinib mesylate targets a specific part of the tyrosine kinase region of Bcr-Abl. Imatinib mesylate is an ATP-mimetic agent that binds Bcr-Abl with greater affinity than ATP at its ATP-binding site. The tyrosine kinase activity of Bcr-Abl is dependent on its ATPase activity. Bcr-Abl–bound imatinib mesylate prevents ATP binding and hydrolysis and hence the tyrosine kinase action of Bcr-Abl. This blocks the downstream substrate of Bcr-Abl, which is dependent on phosphorylation for activation. This in turn blocks downstream signal transduction pathways activated by Bc